The AhR-Siglec-15 axis promotes SHH-MB growth via lysosomal Ca2+ release (ref: Wang doi.org/10.1093/procel/).
Single-cell multi-omics reveals metabolism-linked epigenetic reprogramming as a driver of therapy resistance (ref: Veo doi.org/10.1038/s41467-025-65466-9/).
The Medulloblastoma Meta-Analysis Portal consolidates data from 898 patients for improved risk stratification (ref: Gangwani doi.org/10.1158/0008-5472.CAN-24-4976/).
A predictive signature of 64 epigenetic factors correlates with medulloblastoma prognosis (ref: Francés doi.org/10.3390/cancers17213424/).
2.5D MRI deep learning framework enhances classification of pediatric posterior cranial fossa tumors (ref: Dong doi.org/10.3389/fonc.2025.1700694/).
Potential for repositioning clinically approved therapies based on genomic insights in medulloblastoma (ref: Karaulic doi.org/10.3390/cancers17223659/).